Loading
Everything OnCo dates to 2017: 629 entries, 166 papers, 152 papers listed on people's pages, 130 landmarks and 75 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
629 dated entries in OnCo fall in 2017: 166 papers, 152 papers listed on people's pages, 130 landmarks, 75 trials reported, 53 approvals, 23 regulatory events, 16 companies founded, 5 technologies, 4 journals founded, 3 laws and regulations and 2 guideline changes.
Of those, 20 to the day, 5 to the month and 604 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Imaging agent for visualisation of malignant tissue during glioma surgery (suspected high-grade)
HR+/HER2- advanced breast cancer
Relapsed MCL (accelerated)
First-line ALK+ NSCLC
Merkel cell carcinoma; urothelial cancer after platinum (accelerated)
Relapsed/refractory large B-cell lymphoma ≥2 lines
Newly diagnosed Ph+ CML chronic phase
ALK-positive metastatic NSCLC after crizotinib
First-line advanced RCC (CABOSUN)
First-line ALK-positive metastatic NSCLC
Previously untreated EGFR-expressing RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI.
Relapsed follicular lymphoma after ≥2 therapies. Withdrawn 2023
Newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, adults
BRAF V600E metastatic NSCLC
Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease
Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021)
Relapsed/refractory IDH2-mutated AML
Same
Tissue CGP companion diagnostic (Liquid CDx 2020)
First-line HR+ advanced breast cancer (FALCON)
SomaKit TOC (Ga-68 DOTATOC)
Newly diagnosed and relapsed CD33+ AML
Relapsed/refractory CD22+ B-ALL, adults
Maintenance after autologous transplant
Metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, with fluorouracil and leucovorin: NICE TA440 (26 April 2017) does not recommend it within its marketing a...
First approval globally (Sep 2017)
Topical treatment of mycosis fungoides-type CTCL (Ledaga)
Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis
Untreated metastatic adenocarcinoma of the pancreas with gemcitabine; NICE TA476 (6 September 2017, replacing TA360) recommends it only if other combination chemotherapies are unsu...
Extended adjuvant HER2+ early breast cancer after trastuzumab
Recurrent ovarian cancer maintenance
Companion diagnostic for BRAF, ROS1 and EGFR-directed therapies in NSCLC
Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP)
Previously untreated RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI. TA439 recommends panitumumab within its marketing authorisation subject to the patient acces...
Gastric / GEJ adenocarcinoma, CPS ≥1
Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after at least one chemotherapy.
MSI-H/dMMR solid tumours (tumour-agnostic)
Adjuvant HER2+ early breast cancer at high risk of recurrence
HCC previously treated with sorafenib
HR+/HER2- advanced breast cancer
Adjuvant RCC at high risk (S-TRAC), little used
Same (Xermelo)
Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone
Conditioning before allogeneic HSCT for class 3 beta-thalassaemia in children (Tepadina)
Relapsed/refractory B-ALL, patients up to 25 years
EU first (Aug 2017)
Severe or life-threatening CAR-T-cell-induced cytokine release syndrome, age 2 and over
CE mark, mammography decision support
Ontruzant, first EU trastuzumab biosimilar
First trastuzumab biosimilar (Ogivri); all trastuzumab indications
Erdheim-Chester disease with BRAF V600 mutation
CE-IVD with claims for several PD-1/PD-L1 antibodies
Complementary PD-L1 assay for durvalumab in urothelial carcinoma
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
With aromatase inhibitor, HR+/HER2- advanced breast cancer (MONALEESA-2)
Maintenance in recurrent ovarian cancer regardless of BRCA (NOVA)
Full approval (AURA3)
Full approval (PALOMA-2)
First FLT3 inhibitor approved
Dinutuximab beta (Qarziba)
Urothelial carcinoma (accelerated; later withdrawn 2021)
MSI-H/dMMR solid tumours: first tumour-agnostic approval
Full approval including Ph+ ALL
Breakthrough Therapy designation, HER2+ breast cancer
Single-arm AG221-C-001
Adults
INO-VATE
Maintenance in platinum-sensitive recurrent ovarian cancer; tablet formulation
First CAR-T approval in history
First biosimilar (bevacizumab-awwb) approved
Re-approval at lower fractionated dose for newly diagnosed and relapsed CD33+ AML (ALFA-0701)
EMA approval: first modern PRRT
With fulvestrant after endocrine therapy, and as monotherapy after chemotherapy (MONARCH 2/1)
Relapsed/refractory large B-cell lymphoma after ≥2 lines (ZUMA-1): second CAR-T ever approved
FDA approval and parallel Medicare NCD: first FDA-approved broad CGP companion diagnostic
First trastuzumab biosimilar (Ogivri)
Adjuvant (APHINITY)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
Japan, statute.
United States, statute.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
3 rows added. Anchored to FDA approvals of midostaurin (April 2017, RATIFY), CPX-351 (August 2017), enasidenib (August 2017) and the re-approval of gemtuzumab ozogamicin (September...
1 row added. Anchored to FDA approvals of ribociclib (March 2017) and abemaciclib (September 2017) after palbociclib (2015).
The year reported on trial records, with the headline result the record gives.
Ten-year overall survival 86.3 percent with sentinel node dissection alone against 83.6 percent with axillary clearance (hazard ratio 0.85, non-inferiority p=0.02).
Median overall survival 14.1 against 13.4 months (hazard ratio 0.95, 95 percent confidence interval 0.80 to 1.12) overall, and 11.0 against 10.9 months (0.97, 0.80 to 1.21) in the...
Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017.
Median progression-free survival 34.8 vs 10.9 months (hazard ratio 0.43); 12-month brain progression 9.4% vs 41.4%; 5-year overall survival 62.5% vs 45.5%.
Confirmed objective response rate 45% (90 mg) and 54% (180 mg after a 7-day 90 mg lead-in); median progression-free survival 9.2 and 12.9 months (investigator-assessed, 8.0-month m...
Median total hospital days 10.0 against 12.0 (p=0.03, difference 2.92 days); breathlessness and quality of life equivalent.
Objective response 52.9 percent with irinotecan, temozolomide and dinutuximab against 5.6 percent with temsirolimus in the randomised part; 41.5 percent across all 53 dinutuximab-t...
8-year iDFS HR 0.78; node-positive absolute +4.9%.
Median progression-free survival 14.7 vs 9.2 months (hazard ratio 0.59, masked independent review); median overall survival 34.1 vs 26.8 months (hazard ratio 0.76) in a separate ma...
Median progression-free survival 16.6 vs 8.1 months (hazard ratio 0.55, blinded independent review); response rate 72.5% vs 26.7%; overall survival not significantly different at t...
Nine-year biochemical progression-free survival 83 percent with a low-dose-rate brachytherapy boost against 62 percent with a dose-escalated external beam boost (multivariable haza...
Nivolumab improved overall survival over placebo in heavily pretreated advanced gastric cancer; approved in Japan in September 2017.
Median progression-free survival 10.1 against 4.4 months (hazard ratio 0.30, 95 percent confidence interval 0.23 to 0.41).
OS 51.1 vs 36.4 months; ITT HR 0.81 (p=0.097), per-protocol HR 0.75.
Confirmed objective response 64 percent (23 of 36), with 6 percent complete responses; grade 3 or worse adverse events in 69 percent.
Median overall survival 30.0 with cetuximab against 29.0 months with bevacizumab: no significant difference.
Adjuvant temozolomide: overall survival hazard ratio 0.65; 5-year survival 55.9% vs 44.1%. Concurrent temozolomide benefit confined to IDH-mutant tumours.
OS 9.3 vs 7.6 months, HR 0.67 (95% CI 0.56-0.80).
Median progression-free survival 4.2 against 5.9 months (hazard ratio 1.15, p=0.25) and overall survival 14.4 against 13.2 months (hazard ratio 1.02): the primary endpoint was not...
12-month recurrence-free survival 70.5% vs 60.8% (HR 0.65); 4-year recurrence-free survival 51.7% vs 41.2%; no overall survival difference.
Eight-year overall survival 35.9 against 8.9 percent with ablation added (hazard ratio 0.58).
10-year RFS 48% vs 32%; DMFS 63% vs 48%.
Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months.
No significant difference; twice-daily 45 Gy remains standard.
5-year DFS 74.1% vs 67.6% (HR 0.70); OS 89.2% vs 83.6% (HR 0.59). TNBC subgroup: DFS 69.8% vs 56.1% (HR 0.58), OS 78.8% vs 70.3% (HR 0.52).
6-year OS 93.9% vs 89.4%, HR 0.59.
Disease progression at 24 months in 28 percent after padeliporfin vascular-targeted photodynamic therapy against 58 percent under active surveillance (adjusted hazard ratio 0.34, 9...
Median overall survival 28.0 months with gemcitabine plus capecitabine against 25.5 months with gemcitabine alone (hazard ratio 0.82, p 0.032).
Sensitivity 97%, NPV 99.6% (FIRES).
Median overall survival 24.5, 25.2 and 24.3 months for cabazitaxel 20 mg/m2, cabazitaxel 25 mg/m2 and docetaxel; neither cabazitaxel dose was superior.
Three-year progression-free survival 80.0 percent with obinutuzumab-chemotherapy against 73.3 percent with rituximab-chemotherapy (hazard ratio 0.66, p 0.001); more grade 3 to 5 ad...
Trastuzumab emtansine did not improve overall survival over taxane chemotherapy in previously treated HER2-positive gastric cancer.
Early autologous transplant after RVD lengthened progression-free survival compared with RVD alone, with similar overall survival at first analysis.
5-year local relapse 0.5% (partial breast) vs 1.1% (whole breast), non-inferior; fewer breast changes.
Standard arm DFS HR ~0.45 vs tailored; OS 89% vs 64% at 46 months.
Stopped at the second interim analysis for a large progression-free survival advantage of alectinib over crizotinib.
OS HR 0.66.
ORR 88%, CR 68%, median PFS 15 months (Xi'an cohort, n = 57).
PFS 6.2 vs 4.9 months (HR 0.60, p 0.037); PTEN-low 6.2 vs 3.7 months (HR 0.59, p 0.18). Not confirmed by IPATunity130.
Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years.
PFS HR 0.54; OS 66.8 vs 53.7 months, HR 0.80 (NS).
No melanoma-specific survival benefit; lymphoedema 24% vs 6%.
Nivolumab alone: objective response 24 percent in 37 previously treated patients. Nivolumab with ipilimumab did not improve progression-free survival (3.7 against 2.9 months, hazar...
PFS at 20 months 65.2% vs 10.8% (HR 0.21); ORR 18% vs 3%.
PFS 7.0 vs 4.2 months, HR 0.58; OS 19.3 vs 17.1 months, not significant.
OS HR 0.68; 5-year OS 42.9% vs 33.4%.
All-cause mortality 61.3 against 66.8 percent (hazard ratio 0.84, 95 percent confidence interval 0.70 to 1.01, p=0.06) and prostate cancer mortality 7.4 against 11.4 percent (0.63...
Five-year biochemical and clinical failure-free survival 85 percent in both arms (hazard ratio 0.96, 90 percent confidence interval 0.77 to 1.2); no significant difference in grade...
Multiparametric MRI sensitivity 93 percent against 48 percent for transrectal biopsy, at the cost of specificity (41 against 96 percent); as a triage test it would spare 27 percent...
Median overall survival 13.4 months at cabazitaxel 20 mg/m2 against 14.5 months at 25 mg/m2 (hazard ratio 1.024, upper bound 1.184, non-inferior); grade 3 or 4 adverse events 39.7...
Overall response 88 percent and complete remission 70 percent with risk-stratified sequential treatment; three-year response duration 82 percent; median overall survival 6.6 years...
Median OS 74.7 vs 25.6 months; HR 0.78.
OS 10.6 vs 7.8 months, HR 0.63.
Haematocrit control at week 28: 62% vs 19%.
12-year overall survival 76.3% vs 71.3% (hazard ratio 0.77); benefit mainly with PSA above 0.7 ng/mL.
OS not improved; fewer adverse events.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at fiv...
BuMel > CEM (EFS 50% vs 38%); IL-2 adds no benefit to anti-GD2.
Investigator-assessed response 68.5 per cent in locally advanced and 36.9 per cent in metastatic basal cell carcinoma, with treatment-emergent adverse events in 98 per cent, seriou...
Delaying surgery after 5 x 5 Gy is non-inferior for local recurrence and has fewer postoperative complications.
Median overall survival 23.4 against 22.0 months (hazard ratio 0.93, 95 percent confidence interval 0.79 to 1.10, p=0.415): no benefit.
Median overall survival 11.6 (PCI) vs 13.7 months (MRI surveillance), no benefit.
OS 7.7 vs 4.0 months; HR 0.71.
Survival 96% (137 of 142) with uridine triacetate; historical supportive-care overdose cohort mortality 84% (21 of 25).
High objective and complete response rates in refractory large B-cell lymphoma with durable remissions in a large minority; approved in October 2017.
The publication year on key paper records.
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. The Lancet.
Pan H, Gray R, Braybrooke J, et al. New England Journal of Medicine.
Gnekow AK, Walker DA, Kandels D, et al. European Journal of Cancer.
Rimm DL, Han G, Taube JM, et al. JAMA Oncology.
Masuda N, Lee SJ, Ohtani S, et al. New England Journal of Medicine.
Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Science.
Prince HM, Kim YH, Horwitz SM, et al. The Lancet.
Peters S, Camidge DR, Shaw AT, et al. New England Journal of Medicine.
Trigos AS, Pearson RB, Papenfuss AT, et al. Proceedings of the National Academy of Sciences.
Quigley D, Alumkal JJ, Wyatt AW, et al. Cancer Discovery.
Chan KCA, Woo JKS, King A, et al. New England Journal of Medicine.
Mody R, Naranjo A, Van Ryn C, et al. The Lancet Oncology.
Bussey KJ, Cisneros LH, Lineweaver CH, et al. Proceedings of the National Academy of Sciences.
Bluemn EG, Coleman IM, Lucas JM, et al. Cancer Cell.
von Minckwitz G, Procter M, de Azambuja E, et al. New England Journal of Medicine.
Connor AA, Denroche RE, Jang GH, et al. JAMA Oncology.
Ethun CG, Postlewait LM, Le N, et al. JAMA Surgery.
Rittmeyer A, Barlesi F, Waterkamp D, et al. The Lancet.
Davis C, Naci H, Gurpinar E, et al. BMJ.
Basch E, Deal AM, Dueck AC, et al. JAMA.
Kantarjian H, Stein A, Gökbuget N, et al. New England Journal of Medicine.
Kim DW, Tiseo M, Ahn MJ, et al. Journal of Clinical Oncology.
Kim ES, Bruinooge SS, Roberts S, et al. Journal of Clinical Oncology.
Batlle E, Clevers H. Nature Medicine.
van den Bent MJ, Baumert B, Erridge SC, et al. The Lancet.
Demaria M, O'Leary MN, Chang J, et al. Cancer Discovery.
Carbone DP, Reck M, Paz-Ares L, et al. New England Journal of Medicine.
Weber J, Mandala M, Del Vecchio M, et al. New England Journal of Medicine.
Griffith M, Spies NC, Krysiak K, et al. Nature Genetics.
Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. CA: A Cancer Journal for Clinicians.
McGranahan N, Swanton C. Cell.
Lee JK, Lee J, Kim S, et al. Journal of Clinical Oncology.
Poole R, Kennedy OJ, Roderick P, et al. BMJ.
Siegel RL, Fedewa SA, Anderson WF, et al. JNCI: Journal of the National Cancer Institute.
Long GV, Hauschild A, Santinami M, et al. New England Journal of Medicine.
Palmer AC, Sorger PK. Cell.
Cohen JD, Javed AA, Thoburn C, et al. PNAS.
Huo D, Hu H, Rhie SK, et al. JAMA Oncology.
Wyatt AW, Annala M, Aggarwal R, et al. Journal of the National Cancer Institute.
Faivre-Finn C, Snee M, Ashcroft L, et al. The Lancet Oncology.
Talhouk A, McConechy MK, Leung S, et al. Cancer.
Planchard D, Smit EF, Groen HJM, et al. The Lancet Oncology.
Wu YL, Cheng Y, Zhou X, et al. The Lancet Oncology.
Tsherniak A, Vazquez F, Montgomery PG, et al. Cell.
Shindo K, Yu J, Suenaga M, et al. Journal of Clinical Oncology.
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Nature.
Ohlund D, Handly-Santana A, Biffi G, et al. Journal of Experimental Medicine.
Sahm F, Schrimpf D, Stichel D, et al. The Lancet Oncology.
Goodnow RA, Dumelin CE, Keefe AD. Nature Reviews Drug Discovery.
Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Nature.
Dang CV, Reddy EP, Shokat KM, et al. Nature Reviews Cancer.
Venook AP, Niedzwiecki D, Lenz HJ, et al. JAMA.
Ridker PM, MacFadyen JG, Thuren T, et al. The Lancet.
Stupp R, Taillibert S, Kanner A, et al. JAMA.
Jun JK, Choi KS, Lee HY, et al. Gastroenterology.
Bardia A, Mayer IA, Diamond JR, et al. Journal of Clinical Oncology.
Chen DS, Mellman I. Nature.
Ma WW, Saif MW, El-Rayes BF, et al. Cancer.
Stein EM, DiNardo CD, Pollyea DA, et al. Blood.
Flavahan WA, Gaskell E, Bernstein BE. Science.
Neoptolemos JP, Palmer DH, Ghaneh P, et al. The Lancet.
Arends J, Bachmann P, Baracos V, et al. Clinical nutrition (Edinburgh, Scotland).
Esteva A, Kuprel B, Novoa RA, et al. Nature.
Turner KM, Deshpande V, Beyter D, et al. Nature.
Soria JC, Tan DSW, Chiari R, et al. The Lancet.
Balar AV, Castellano D, O'Donnell PH, et al. The Lancet Oncology.
Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, et al. JAMA Oncology.
Ashkenazi A, Fairbrother WJ, Leverson JD, et al. Nature Reviews Drug Discovery.
Marcus R, Davies A, Ando K, et al. New England Journal of Medicine.
Seddon B, Strauss SJ, Whelan J, et al. The Lancet Oncology.
Taylor RA, Fraser M, Livingstone J, et al. Nature Communications.
Hahnen E, Lederer B, Hauke J, et al. JAMA Oncology.
Galdy S, Lamarca A, McNamara MG, et al. Cancer Metastasis Reviews.
Gershenson DM, Bodurka DC, Coleman RL, et al. Journal of Clinical Oncology.
Ladenstein R, Pötschger U, Pearson ADJ, et al. The Lancet Oncology.
Davies H, Glodzik D, Morganella S, et al. Nature Medicine.
Singhi AD, Ali SM, Lacy J, et al. Journal of the National Comprehensive Cancer Network.
Balachandran VP, Luksza M, Zhao JN, et al. Nature.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. The Lancet Haematology.
Attal M, Lauwers-Cances V, Hulin C, et al. New England Journal of Medicine.
Papillon-Cavanagh S, Lu C, Gayden T, et al. Nature Genetics.
Blay JY, Soibinet P, Penel N, et al. Annals of Oncology.
Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Nature.
Cancer Genome Atlas Research Network (Raphael BJ, Hruban RH, Aguirre AJ, et al.). Cancer Cell.
Mackay A, Burford A, Carvalho D, et al. Cancer Cell.
Zhang J, Cunningham JJ, Brown JS, et al. Nature Communications.
Ferrell BR, Temel JS, Temin S, et al. Journal of Clinical Oncology.
Cavalli FMG, Remke M, Rampasek L, et al. Cancer Cell.
Kim SB, Dent R, Im SA, et al. The Lancet Oncology.
Gronchi A, Ferrari S, Quagliuolo V, et al. The Lancet Oncology.
Romero R, Romero R, Sayin VI, et al. Nature Medicine.
Faubert B, Li KY, Cai L, et al. Cell.
Fizazi K, Tran N, Fein L, et al. New England Journal of Medicine.
Le DT, Durham JN, Smith KN, et al. Science.
Li T, Fan J, Wang B, et al. Cancer Research.
Makohon-Moore AP, Zhang M, Reiter JG, et al. Nature Genetics.
Atkin W, Wooldrage K, Parkin DM, et al. The Lancet.
Symmans WF, Wei C, Gould R, et al. Journal of Clinical Oncology.
Sekulic A, Migden MR, Basset-Seguin N, et al. BMC cancer.
Woodcock J, LaVange LM. New England Journal of Medicine.
Gershenwald JE, Scolyer RA, Hess KR, et al. CA: A Cancer Journal for Clinicians.
Sepulveda AR, Hamilton SR, Allegra CJ, et al. Journal of Clinical Oncology.
Sledge GW, Toi M, Neven P, et al. Journal of Clinical Oncology.
Guedes LB, Antonarakis ES, Schweizer MT, et al. Clinical Cancer Research.
Faries MB, Thompson JF, Cochran AJ, et al. New England Journal of Medicine.
Brown PD, Ballman KV, Cerhan JH, et al. The Lancet Oncology.
Childers CP, Childers KK, Maggard-Gibbons M, et al. Journal of Clinical Oncology.
Morris VK, Salem ME, Nimeiri H, et al. The Lancet Oncology.
Strosberg J, El-Haddad G, Wolin E, et al. New England Journal of Medicine.
D'Angelo SP, Larkin J, Sosman JA, et al. Journal of Clinical Oncology.
Overman MJ, McDermott R, Leach JL, et al. Lancet Oncology.
Chang HHY, Pannunzio NR, Adachi N, et al. Nature reviews. Molecular cell biology.
Jones JC, Renfro LA, Al-Shamsi HO, et al. Journal of Clinical Oncology.
Robson M, Im SA, Senkus E, et al. New England Journal of Medicine.
Chakravarty D, Gao J, Phillips SM, et al. JCO Precision Oncology.
Mok TS, Wu Y-L, Ahn M-J, et al. New England Journal of Medicine.
Antonia SJ, Villegas A, Daniel D, et al. New England Journal of Medicine.
Lutz S, Balboni T, Jones J, et al. Practical radiation oncology.
Lord CJ, Ashworth A. Science.
Coles CE, Griffin CL, Kirby AM, et al. The Lancet.
Hirsch FR, McElhinny A, Stanforth D, et al. Journal of Thoracic Oncology.
Bellmunt J, de Wit R, Vaughn DJ, et al. New England Journal of Medicine.
Bauml J, Seiwert TY, Pfister DG, et al. Journal of Clinical Oncology.
Abbosh C, Birkbak NJ, Wilson GA, et al. Nature.
Wilt TJ, Jones KM, Barry MJ, et al. New England Journal of Medicine.
Pietrasz D, Pecuchet N, Garlan F, et al. Clinical Cancer Research.
van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al. Nature reviews. Urology.
Peinado H, Zhang H, Matei IR, et al. Nature Reviews Cancer.
Win AK, Jenkins MA, Dowty JG, et al. Cancer Epidemiology, Biomarkers & Prevention.
Tejpar S, Stintzing S, Ciardiello F, et al. JAMA Oncology.
Arnold D, Lueza B, Douillard JY, et al. Annals of Oncology.
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. The Lancet.
Takahashi T, Yamanaka T, Seto T, et al. The Lancet Oncology.
Jordan EJ, Kim HR, Arcila ME, et al. Cancer Discovery.
Trappe RU, Dierickx D, Zimmermann H, et al. Journal of Clinical Oncology.
Kastenhuber ER, Lowe SW. Cell.
Shipley WU, Seiferheld W, Lukka HR, et al. New England Journal of Medicine.
Ligibel JA, Barry WT, Alfano C, et al. NPJ breast cancer.
Stone RM, Mandrekar SJ, Sanford BL, et al. New England Journal of Medicine.
Ku SY, Rosario S, Wang Y, et al. Science.
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Annals of Oncology.
Jo VY, Chau NG, Hornick JL, Krane JF, Sholl LM. Modern Pathology.
Hsieh JJ, Purdue MP, Signoretti S, et al. Nature reviews. Disease primers.
Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, et al. Diabetologia.
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Pancreatology.
Van Poznak C, Somerfield MR, Barlow WE, et al. Journal of Clinical Oncology.
Tawbi HA, Burgess M, Bolejack V, et al. The Lancet Oncology.
Nangia J, Wang T, Osborne C, et al. JAMA.
Jänne PA, van den Heuvel MM, Barlesi F, et al. JAMA.
Perry JR, Laperriere N, O'Callaghan CJ, et al. New England Journal of Medicine.
Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.
Mu P, Zhang Z, Benelli M, et al. Science.
James ND, de Bono JS, Spears MR, et al. New England Journal of Medicine.
Li MM, Datto M, Duncavage EJ, et al. The Journal of molecular diagnostics.
Irwin MR, Olmstead R, Carrillo C, et al. Journal of Clinical Oncology.
Nelson KM, Dahlin JL, Bisson J, et al. Journal of medicinal chemistry.
Prasad V, De Jesús K, Mailankody S. Nature Reviews Clinical Oncology.
Aster JC, Pear WS, Blacklow SC. Annual review of pathology.
Jamal-Hanjani M, Wilson GA, McGranahan N, et al. (TRACERx Consortium). New England Journal of Medicine.
Bradner JE, Hnisz D, Young RA. Cell.
Riaz N, Havel JJ, Makarov V, et al. Cell.
van der Weyden CA, Pileri SA, Feldman AL, et al. Blood cancer journal.
Martincorena I, Raine KM, Gerstung M, et al. Cell.
Hayward NK, Wilmott JS, Waddell N, et al. Nature.
Cramer H, Lauche R, Klose P, et al. The Cochrane database of systematic reviews.
Neelapu SS, Locke FL, Bartlett NL, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Colorectal cancer. The UK Flexible Sigmoidoscopy Screening Trial, 170,034 people, reported a 26 percent lower incidence and a 30 percent lower mortality in those invited, and 35 an...
Mantle cell lymphoma
Germ cell tumours of childhood and adolescence (extracranial and CNS). Joint COG/CCLG trial of active surveillance and carboplatin versus cisplatin.
Triple-negative breast cancer (TNBC). Grade, ER, PR and HER2 enter the stage group alongside TNM (Giuliano, CA); validated in 2018.
Gallbladder cancer. T2 is split into T2a and T2b and N stage is defined by the number of involved nodes (N1 one to three, N2 four or more).
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)
Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
ALK-positive non-small-cell lung cancer
Early HER2-positive breast cancer
Retinoblastoma
Primary CNS lymphoma. IELSG32 second randomisation and PRECIS.
Merkel cell carcinoma. JAVELIN Merkel 200; accelerated approval March 2017.
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
Primary mediastinal (thymic) large B-cell lymphoma
Biliary tract cancer (cholangiocarcinoma)
Astrocytoma, IDH-mutant (grades 2 to 4)
Hepatoblastoma
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Melanoma
BRAF V600-mutant melanoma
Limited-stage small-cell lung cancer
Small-cell lung cancer
Secondary and therapy-related acute myeloid leukaemia
Triple-negative breast cancer (TNBC). 910 patients; five-year overall survival 89.2 vs 83.6 percent, and 78.8 vs 70.3 percent in the triple-negative group.
Early triple-negative breast cancer
BRAF V600E-mutant non-small-cell lung cancer
Oral cavity cancer (mouth and tongue)
Oral tongue and floor of mouth cancer
Meningioma. Sahm and colleagues (Lancet Oncology).
Nasopharyngeal carcinoma
Stage IIB and IIC melanoma
IDH1- and IDH2-mutated acute myeloid leukaemia
Resectable pancreatic ductal adenocarcinoma
Mismatch-repair deficient (MSI-high) colorectal cancer
Endometrial cancer
Non-Hodgkin lymphoma (all types). Axicabtagene ciloleucel approved for relapsed large B-cell lymphoma after two or more lines.
Childhood cancers (all types). Tisagenlecleucel for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Gallbladder cancer. The Indian genome-wide association study finds common variants at ABCB1 and ABCB4 that raise gallbladder cancer risk.
Metastatic cancer (cancer that has spread). Pembrolizumab is approved for any solid tumour with mismatch-repair deficiency or microsatellite instability, the first cancer drug appr...
HER2-positive breast cancer
Acute myeloid leukaemia. Midostaurin (RATIFY), enasidenib, CPX-351, gemtuzumab re-approval; the first new AML drugs since 2000.
HER2-positive gastric cancer
Uterine sarcoma. Seddon and colleagues, Lancet Oncol; doxorubicin retained as first line.
Acute myeloid leukaemia in children
High-risk neuroblastoma
Neuroblastoma (paediatric)
Primary CNS lymphoma
Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Dogan and colleagues; Jo and colleagues.
Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
Newly diagnosed multiple myeloma, transplant-eligible
Penile cancer. International phase 3 platform for node-positive penile cancer (NCT02305654).
Node-positive and metastatic penile cancer
Sarcomas (soft tissue, bone, GIST)
Undifferentiated pleomorphic sarcoma (UPS)
Soft tissue sarcoma of the extremity (localised and advanced)
Small-cell lung cancer
PD-L1-high gastric cancer
Rosai-Dorfman-Destombes disease
Acute lymphoblastic leukaemia. ELIANA-based approval for ALL up to age 25; TOWER OS 7.7 vs 4.0 months.
Metastatic hormone-sensitive prostate cancer
Prostate cancer
Lung neuroendocrine tumours (typical and atypical carcinoid)
Essential thrombocythaemia (ET). Ruxolitinib matched but did not beat best available therapy after hydroxyurea failure, though it eased symptoms.
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Acute myeloid leukaemia
Locally advanced and metastatic basal cell carcinoma
Stage III melanoma (after surgery)
Brain metastases (secondary brain tumours)
Metastatic and recurrent anal squamous cell carcinoma
Pancreatic ductal adenocarcinoma. Survivors have both many high-quality neoantigens and abundant CD8 T cells, and lose those clones at metastasis; TCGA fixes the driver list and sh...
Small intestinal neuroendocrine tumours
Basal cell carcinoma. TA489 recommendation 1.1 does not recommend vismodegib for metastatic or locally advanced basal cell carcinoma, on uncertain evidence and a cost per quality-a...
Anal cancer (squamous cell carcinoma)
Gastric & gastro-oesophageal junction cancer
Follicular lymphoma
Metastatic triple-negative breast cancer
Non-small-cell lung cancer. The Blueprint comparison shows three PD-L1 assays agree on tumour cells and SP142 does not.
Unresectable stage III non-small-cell lung cancer
Non-small-cell lung cancer
Early-onset colorectal cancer (under 50)
Rare cancers of childhood (NCI PDQ umbrella). Molecular assignment platform for any refractory childhood solid tumour.
Relapsed and refractory classical Hodgkin lymphoma
Advanced and metastatic small bowel adenocarcinoma
Bladder & urothelial cancer
Gestational trophoblastic neoplasia
High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Microsatellite-unstable (MSI-high) gastric cancer
Placental-site trophoblastic tumour and epithelioid trophoblastic tumour
Small intestine cancer (small bowel adenocarcinoma). Small bowel adenocarcinoma is one of the eligible tumours.
Colorectal cancer. Based on KEYNOTE-016/164 and others; dMMR CRC becomes the model immunotherapy-responsive GI tumour.
Mismatch-repair-deficient endometrial cancer
Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)
Prostate cancer. Above a 2% tumour fraction, plasma reproduces every somatic mutation found in a matched metastatic biopsy, which is the number that makes a liquid biopsy reportabl...
Mucosal melanoma
Medulloblastoma
FLT3-mutated acute myeloid leukaemia
Neuroendocrine and small-cell prostate cancer
Gallbladder cancer. Ethun and colleagues, ten US centres, 207 patients; a 2026 individual patient data meta-analysis found no difference by timing.
Prostate cancer. Mu and Ku showed that losing TP53 and RB1 lets a prostate cancer cell switch on SOX2 and stop needing the androgen receptor, reversibly in the laboratory.
Advanced hepatocellular carcinoma (BCLC C)
Hepatocellular carcinoma
Post-transplant lymphoproliferative disorder (PTLD). Rituximab consolidation alone for complete responders (JCO 2017).
Biochemical recurrence of prostate cancer
Malignant peripheral nerve sheath tumour (MPNST)
Undifferentiated pleomorphic sarcoma (UPS)
Oropharyngeal cancer (tonsil and base of tongue)
HPV-positive oropharyngeal cancer
Glioma & glioblastoma
Colorectal cancer. Across six randomised trials, EGFR antibodies helped left-sided RAS wild-type tumours (hazard ratio 0.75) and not right-sided ones (1.12); non-V600 BRAF mutation...
Early-onset colorectal cancer (under 50)
Lung cancer (all types). PACIFIC put durvalumab after chemoradiotherapy, reaching 42.9 percent five-year survival against 33.4; ALEX moved first-line ALK treatment to a brain-penet...
Basal cell carcinoma. 1,215 patients in 36 countries: response 68.5 per cent in locally advanced disease, adverse events in 98 per cent and a median treatment duration of 8.6 month...
Newly diagnosed multiple myeloma, transplant-ineligible
Extensive-stage small-cell lung cancer
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Uterine carcinosarcoma
Relapsed and refractory acute lymphoblastic leukaemia in children
Acute lymphoblastic leukaemia
Leukaemia (all types)
Thymoma and thymic carcinoma
Pancreatic ductal adenocarcinoma. T1 to T3 by size (2 and 4 cm), N1 and N2 by one to three and four or more nodes; validated in 2,318 resections from three US centres and 8,960 SEE...
Thymoma (WHO types A, AB, B1, B2 and B3)
Erdheim-Chester disease
Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. First approval for any histiocytosis (VE-BASKET); November 2017.
Lip cancer
Mucoepidermoid carcinoma
Grade 3 well-differentiated neuroendocrine tumour
Breast cancer (all types). Ten-year overall survival 86.3 percent without completion clearance against 83.6 percent with it.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Shanghai
Shanghai
Homburg
Suzhou
Boston, Massachusetts
Nanjing / Shanghai
Geneva
Shanghai
Waltham, MA
Waltham, MA
Boston, MA
Toowong, Brisbane
Montpellier
San Diego, CA
Kawasaki
Shanghai
The founded year on journal records.
Elsevier
American Society of Clinical Oncology
American Society of Clinical Oncology
Oxford University Press
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Oncotarget
Cancer Discovery
Eur Arch Otorhinolaryngol
Journal of Oncology Practice
Science Translational Medicine
NEJM
New England Journal of Medicine
NEJM
NEJM
NEJM
New England Journal of Medicine
Current Opinion in Oncology
NEJM
Nature
Cancer Research and Treatment
ACS Nano
JAMA
JAMA Oncology
NEJM
The Lancet Oncology
Annals of Oncology
Lancet Oncol
Lancet Oncology
The Lancet Oncology
Lancet
NEJM
Indian Journal of Cancer
Nature
Lancet
NEJM
Cell
Surgery
Lancet Oncology
Annals of Oncology
Blood
Clinical Cancer Research
Cell
Lancet
Radiotherapy and Oncology
Lancet Oncology
Annals of Surgery
Iranian Journal of Pathology
NEJM
Cancer Discovery
European Urology
Critical Reviews in Oncology/Hematology
JAMA
JAMA
JAMA
Diabetol Metab Syndr
European Journal of Cancer
Clinical Cancer Research
Blood
Lancet Respiratory Medicine
Radiother Oncol
The Lancet Oncology
JNCI: Journal of the National Cancer Institute
Physics in Medicine and Biology
Lancet Oncology
ESMO Open
Journal of Nuclear Medicine
JAMA Oncology
Molecular Therapy Methods & Clinical Development
The Lancet
Science
Lancet Oncology
Nature
PLOS ONE
JCO
Scientific Reports
Cell
Cancer Cell
Cell Death & Disease
Lancet
Cancer Cell
Gastroenterology
Cancer Research and Treatment
The Lancet Oncology
JCO
Blood
Nature Reviews Cancer
New England Journal of Medicine
Nature Reviews Molecular Cell Biology
New England Journal of Medicine
NEJM
Oncogenesis
Science
Proceedings of the National Academy of Sciences
Journal of Clinical Oncology
Oral Oncology
Nature Medicine
Cell Death & Disease
Lancet
Lancet Oncology
Neurology India
New England Journal of Medicine
JAMA
Journal of Clinical Oncology
European Journal of Cancer
Journal of Cancer Education
NEJM
The Lancet
Nature
Lancet
New England Journal of Medicine
NEJM
Journal of Clinical Oncology
Nature Communications
Diabetes Ther
Cancer Discovery
Prostate Cancer and Prostatic Diseases
Am J Trop Med Hyg
Lancet Oncol
Annals of Translational Medicine
BMC Cancer
Cell
Journal of Clinical Oncology
Nature Reviews Clinical Oncology
Journal of Clinical Oncology
Journal of Clinical Oncology
Critical Care
International Journal of Endocrinology
Journal of Clinical Oncology
Indian Journal of Palliative Care
Lancet
Blood
The Lancet Oncology
Cancer Discovery
The Lancet Oncology
Nature Communications
Epilepsia
Lancet Oncology
European Urology
Journal of Clinical Oncology
Ultraschall in der Medizin - European Journal of Ultrasound
The Oncologist
European Journal of Cancer
Nature Reviews Clinical Oncology
Nature
Cancer Cell
Annals of Oncology
Genome Biology
Tumori Journal
Lancet Oncology
Diabetes Care
Nature Communications
The Lancet Oncology
Annals of Surgery
J Clin Sleep Med
The Lancet Respiratory Medicine
Annals of Oncology
Lancet Oncology